Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)

NCT05246722 — Unknown, 15000 participants, Beijing Anzhen Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease

Registry	NCT05246722
Status	Unknown
Study type	Observational
Enrollment	15000 (Estimated)
Sponsor	Beijing Anzhen Hospital (Other)
Conditions	Elderly Patients, Coronary Heart Disease, Drug Therapy, Clinical Outcomes
Dates	start 2022-02-01 (estimated), primary completion 2024-12-01 (estimated), completion 2025-12-01 (estimated), first posted 2022-02-18, last updated 2022-02-18

-Summary

A registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease

Expand all sections · Collapse all

+Outcome measures

Primary outcomes

main adverse cardiovascular and cerebrovascular events (MACCE) [up to 3 years]: MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization

Secondary outcomes

Adverse drug reaction [up to 3 years]: Adverse drug reaction will be defined as any adverse reactions in the patients

+Eligibility

Sex: All, ages: 65 Years to any

Inclusion Criteria:

* Informed consent has been signed
* Patients diagnosed in our hospital with coronary heart disease
* Age ≥65 years

Exclusion Criteria:

* Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.
* Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.